Kraj: Izrael
Język: angielski
Źródło: Ministry of Health
DESONIDE
PERRIGO ISRAEL AGENCIES LTD
D07AB08
CREAM
DESONIDE 0.1 %
TOPICAL
Required
PIERRE FABRE MEDICAMENT PRODUCTION, FRANCE
DESONIDE
DESONIDE
Treatment of dermatoses which require treatment with topical corticosteroids e.g. psoriasis, lichenipication, atopic dermatitis, contact dermatitis
2014-04-30
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT LOCATOP® 0.1 °/O, CREAM 2 . QUALITATIVE AND QUANTITATIVE COMPOSITION Desonide .........................................................................0.100 g for 100 g of cream Excipient with specific effect: sorbic acid. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Cream 4. CLINICAL PARTICULARS 4.1. T HERAPEUTIC INDICATION Treatment of dermatoses which require treatment with topical corticosteroids e.g. psoriasis, lichenipication, atopic dermatitis, contact dermatitis 4.2. P OSOLOGY AND METHOD OF ADMINISTRATION LOCATOP® Cream should be applied to the affected areas as a thin film limited to two times daily, each rubbed in gently. An excessive increase in the number of applications per day risks aggravating the adverse effects without improving the therapeutic effects. Treatment of large areas required monitoring of the number of tubes used. For rational use, it is advisable to apply the product as small amounts spaced out, then spread with a plastic glove until fully absorbed. Gradual withdrawal is advisable in some dermatoses (psoriasis, atopic dermatitis, etc.). This may be done by reducing the frequency of applications and/or by using a less potent or less concentrated corticoid. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. LOCATOP® Cream should not be used with occlusive dressings. 4.3 CONTRAINDICATIONS: Hypersensitivity to any of the ingredient contained in this medicinal product. - Primary bacterial, viral or fungal infections or parasitical infections even if they include an inflammatory component. - Ulcerated lesions. - Acne. - Rosacea. 4.4 SPECIAL WARNING AND PRECAUTIONS FOR USE Special warnings Prolonged use of highly active corticoids on the face leads to a risk of corticoid-induced and paradoxically corticoid-sensitive dermatitis with rebound after each withdrawal. Gradual wea Przeczytaj cały dokument